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Objective: To evaluate the accuracy of a computer-aided evaluation program (CAE) of breast MRI for the assessment of 
residual tumor extent and response monitoring in breast cancer patients receiving neoadjuvant chemotherapy.
Materials and Methods: Fifty-seven patients with breast cancers who underwent neoadjuvant chemotherapy before surgery 
and dynamic contrast enhanced MRI before and after chemotherapy were included as part of this study. For the assessment 
of residual tumor extent after completion of chemotherapy, the mean tumor diameters measured by radiologists and CAE 
were compared to those on histopathology using a paired student t-test. Moreover, the agreement between unidimensional 
(1D) measurement by radiologist and histopathological size or 1D measurement by CAE and histopathological size was 
assessed using the Bland-Altman method. For chemotherapy monitoring, we evaluated tumor response through the change 
in the 1D diameter by a radiologist and CAE and three-dimensional (3D) volumetric change by CAE based on Response 
Evaluation Criteria in Solid Tumors (RECIST). Agreement between the 1D response by the radiologist versus the 1D response 
by CAE as well as by the 3D response by CAE were evaluated using weighted kappa (k) statistics. 
Results: For the assessment of residual tumor extent after chemotherapy, the mean tumor diameter measured by 
radiologists (2.0 ± 1.7 cm) was significantly smaller than the mean histological diameter (2.6 ± 2.3 cm) (p = 0.01), 
whereas, no significant difference was found between the CAE measurements (mean = 2.2 ± 2.0 cm) and histological 
diameter (p = 0.19). The mean difference between the 1D measurement by the radiologist and histopathology was 0.6 cm 
(95% confi  dence interval: -3.0, 4.3), whereas the difference between CAE and histopathology was 0.4 cm (95% confi  dence 
interval: -3.9, 4.7). For the monitoring of response to chemotherapy, the 1D measurement by the radiologist and CAE 
showed a fair agreement (k = 0.358), while the 1D measurement by the radiologist and 3D measurement by CAE showed 
poor agreement (k = 0.106).
Conclusion: CAE for breast MRI is sufficiently accurate for the assessment of residual tumor extent in breast cancer 
patients receiving neoadjuvant chemotherapy. However, for the assessment of response to chemotherapy, the assessment 
by the radiologist and CAE showed a fair to poor agreement.
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INTRODUCTION
Neoadjuvant chemotherapy has been increasingly used in 
patients with operable breast cancers as well as those with 
locally advanced breast cancers. The use of neoadjuvant 
chemotherapy has allowed formerly unresectable tumors to 
be resectable and has increased the proportion of breast 
conservation surgery (1-5). Several studies have shown 
that the size of residual tumors and the response of a tumor 
to neoadjuvant chemotherapy are related to the recurrence-
free survival rate and thus, a more accurate evaluation 
of residual tumor extent and response monitoring to 
chemotherapy have become of paramount importance in 
clinical practice as well as in research trials (6-10). In 
2000, the collaboration between the European Organization 
for Research and Treatment of Cancer, National Cancer 
Institute of the United States and National Cancer Institute 
of Canada Clinical Trials Group suggested the use of 
Response Evaluation Criteria in Solid Tumors (RECIST) using 
unidimensional (1D) measurements (11). The use of these 
criteria has become commonly accepted as the standard 
in the evaluation of tumor response. However, several 
limitations of the use of these criteria have been reported 
and the modifi  cation of RECIST has become necessary (12). 
It has been proposed that the use of three-dimensional (3D) 
volumetric assessment rather than 1D assessment should be 
considered (13).
The recent advent of high resolution dynamic contrast-
enhanced MRI has provided 3D information of the anatomy 
and perfusion of breast cancer, thus enabling the extent of 
the disease to be assessed accurately after chemotherapy 
(14-20). However, after chemotherapy, MRI often under-
estimates or over-estimates the extent of disease due to 
changes in cellularity or vascularity of tumors (21, 22). 
Moreover, a volumetric measurement is a particularly labor 
intensive endeavor that requires much time and effort.
It has been suggested that a computer-aided evaluation 
program (CAE) of breast MRI using automatic segmentation 
might be helpful in determining disease extent, but a recent 
study has shown that CAE of breast MRI was less accurate 
than a radiologist in the assessment of tumor size in breast 
cancer patients undergoing neoadjuvant chemotherapy (23). 
However, the investigation was only a small pilot study that 
included 15 patients. Controversy remains as to whether 
CAE is accurate for MRI of breast cancer patients who were 
treated with neoadjuvant chemotherapy.
Therefore, the purpose of this study was to evaluate the 
accuracy of CAE in breast MRI for the assessment of residual 
tumor extent and the monitoring of chemotherapeutic 




Our Institutional Review Board approved this study and 
informed consent was waived for this retrospective analysis. 
Between December 2006 and April 2008, 76 consecutive 
patients with breast cancer underwent breast MRI before 
and after neoadjuvant chemotherapy and curative surgery 
at our institution. Nineteen patients were excluded due to 
data loading errors in the application of the CAE. These 
data loading errors might be explained by the unavailability 
of the CAE system for the oblique sagittal images. The CAE 
system used in this study was designed for right-angled 
sagittal images, so, some images were not loaded according 
to the scanned angle. Ultimately, 114 MRI examinations 
of 57 patients were included in the study. Patient 
characteristics are summarized in Table 1. Mean patient age 
for this study was 44 years old (range, 24-64). All patients 
had undergone a core needle biopsy for diagnosis and two 
separate breast MRI examinations; one examination prior to 
neoadjuvant chemotherapy and the other examination after 
completion of chemotherapy and prior to fi  nal surgery. The 
mean interval between completion of chemotherapy and the 
second MRI examination was 21.1 days (range, 8-51 days). 
The mean interval between the second MRI examination 
and surgery was 5.1 days (range, 1-21 days). Forty-
seven patients (82%) received taxane plus anthracycline 
regimens (three cycles for 45 patients and six cycles for 
two patients), whereas two patients (4%) received an 
anthracycline-based regimen (three cycles for one patient 
and four cycles for the other patient). The remaining eight 
patients (14%) received a trastuzumab plus taxane regimen 
(six cycles for all patients). The mean durations of the 
respective neoadjuvant chemotherapies were 49 days for 
patients who received taxane plus anthracycline, 54 days 
for patients who received anthracycline, and 112 days for 
patients who received trastuzumab plus taxane. The mean 
interval between the 1st and 2nd MRI examination was 80 
days (range, 57-99 days) for patients who received three 
cycles of chemotherapy and 145 days (range, 124-176 days) 
for six cycles.Korean J Radiol 12(1), Jan/Feb 2011 www.kjronline.org 36
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MRI Examinations
The MRI protocol was performed with a 1.5 Tesla system 
(Signa, GE Healthcare, Milwaukee, WI) using a dedicated 
breast coil (8-channel HD breast array, GE Healthcare, 
Milwaukee, WI). After an axial localizer image, fat-
suppressed T2-weighted fast spin-echo sagittal images were 
obtained (TR/TE, variable from 5500 to 7150/82; 256 × 160 
matrix; fi  eld of view: 200 × 200 mm; 1.5-mm slice thickness; 
no gap). Dynamic contrast-enhanced examinations included 
one pre-contrast and fi  ve post-contrast, bilateral sagittal 
image acquisitions using a fat-suppressed T1-weighted 3D 
fast spoiled gradient echo sequence (TR/TE, 6.5/2.5; matrix 
256 × 160; fl  ip angle 10°; fi  eld of view 200 × 200 mm; 1.5-
mm slice thickness; no gap). Gadobenate dimeglumine (0.1 
mmol/kg Multihance; Bracco Imaging, Milan, Italy) was 
injected using an automated injector (Spectris MR, Medrad 
Europe, Maastricht, The Netherlands) through an indwelling 
IV catheter. Five post-contrast image series were obtained 
at 76, 165, 345, 434, and 583 seconds after contrast 
administration. For all studies, early subtraction (i.e., fi  rst 
postcontrast images minus pre-contrast images), axial 
reformatted images, and 3D maximum intensity projection 
images were generated.
Computer-Aided Evaluation Program
For the CAE measurements, an early 1st post-contrast 
series (obtained at 76 seconds after contrast injection), 
and four late post-contrast image series (obtained at 
165, 345, 434, and 583 seconds after contrast injection) 
were transferred to a commercially available MR CAE 
(CADSTREAM™ version 4.1.3,  Confi  rma, Inc., Kirkland, WA) 
workstation and processed. A color overlay map was placed 
on all enhancing lesions at the enhancement threshold 
level in a pixel by pixel comparison across a pre-contrast, 
early and late post-contrast series. The users could choose 
a 50% or a 100% enhancement threshold. In this study, we 
chose the 50% enhancement threshold because, according 
to several previous studies, the 50% threshold was more 
sensitive than the 100% threshold in the detection (24, 
25) of slowly enhancing lesions frequently found in the 
neoadjuvant chemotherapy setting.
Delayed phase enhancement type after peak enhancement 
was classifi  ed as persistent, plateau, or washout (26) and 
appeared as different colors; blue for persistent, yellow 
for plateau, and red for washout. The CAE automatically 
segmented and calculated the longest diameter and 
volume of the all enhancing components (23, 25). Manual 
segmentation was not available for scattered multiple 
lesions or lesions with an irregular shape for this CAE 
system. The same radiologists, who had performed a 1D 
measurement at a PACS workstation, selected the same 
lesions for CAE measurement.
Measurement of Tumor Extent
The one-dimensional measurements were performed by 
two radiologists with eight and three years of experience 
in the interpretation of breast MRI and retrospectively 
analyzed pre- and post-chemotherapy MR images in 
consensus. At the time of tumor measurement, the 
radiologists were not aware of the histopathology 
information. A positive lesion was defi  ned as when the 
signal intensity of the lesion was higher than that of the 
breast parenchyma, as seen on early subtraction images. 
The lesion size was measured as the longest diameter of 
Table 1. Clinical Characteristics of 57 Study Patients
No. of Patients (%)
Neoadjuvant chemotherapy regimen
     Anthracycline based   2 (4)
   Taxane plus anthracycline 47 (82)
   Taxane plus trastuzumab   8 (14)
Pre-chemotherapy clinical stage
   IIB   7 (12)
   IIIA 40 (70)
   IIIB   4 (7)
   IIIC   6 (11)
Post-chemotherapy pathologic stage
   0*   7 (12)
   I   6 (11)
   IIA 12 (21)
   IIB 12 (21)
   IIIA 14 (25)
   IIIB   0
   IIIC   6 (11)
Histological type
   Invasive ductal 56 (98)
   Invasive lobular   1 (2)
Surgical method
   Total mastectomy 25 (44)
   Partial mastectomy 32 (56)
Note.—*Surgical histology revealed no residual tumor.Korean J Radiol 12(1), Jan/Feb 2011 www.kjronline.org 37
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the lesion on 21 inch monitors at a picture archiving and 
communication system (PACS) workstation using electronic 
calipers. Target lesions included up to a maximum of fi  ve 
lesions per breast, as seen on fi  rst post-contrast images. 
For multiple lesions, the longest diameter of each lesion 
was separately recorded and the sum of the lesions was 
calculated. When there was no enhancing lesion seen on 
fi  rst post-contrast images, the lesion size was set to 0 cm.
Assessment of Treatment Response
We evaluated the tumor response for the neoadjuvant 
chemotherapy according to the three following modalities: 
1D measurement by radiologists as well as 1D and 3D 
measurements by CAE according to the RECIST criteria. 
For 1D tumor measurements, according to RECIST, the 
responders group consisted of patients with a complete 
response (CR) (no enhancing lesion detected on post-
chemotherapy MRI) or partial response (PR) (≥ 30% 
reduction of the sum of maximal diameters) to treatment (11, 
27). The non-responders group consisted of patients with 
stable disease (SD) (< 30% reduction or a < 20% increase of 
the sum of maximal diameters) or progressive disease (PD) (≥ 
20% increase of the sum of maximal diameters). 
For 3D volumetric measurements, based on the 
assumption that the tumor was spherical, PR was defi  ned for 
tumors with a ≥ 65% reduction in the sum of volumes from 
the baseline level, and SD was defi  ned for tumors with a < 
65% reduction or a < 73% increase of the sum of volumes 
from the baseline level (27). If a tumor had a radius (r), 
the tumor volume would be calculated as 4/3 πr
3. Therefore, 
a 30% diameter reduction of the tumor corresponded to 
the 65% volume reduction, and a 20% diameter increase 
of the tumor corresponded to the 73% volume increase. PD 
was defi  ned for tumors with a 73% increase of the sum of 
volumes or the appearance of a new lesion. Patients were 
divided into two groups-responders and non-responders-
according to RECIST and volumetric measurement, 
respectively.
Histopathological Analysis
After a partial or total mastectomy, a pathologist 
evaluated mastectomy specimens with serial 10 mm 
sections along the longitudinal axis. For the assessment 
of tumor size, grossly apparent lesions in the sliced tissue 
were measured and size estimates for smaller lesions 
obtained microscopically were included. Standardized 
report templates included the number and sizes of 
measurable invasive components as well as the carcinoma 
in situ components of the tumor. Histopathological tumor 
diameter was defi  ned as the sum of the longest diameters 
of all invasive components of the tumor as stated in 
the histopathology report. The maximum diameter by 
histopathology was used as a reference standard.
Data and Statistical Analysis
The mean of residual tumor extents after neoadjuvant 
chemotherapy were compared between the radiologists or 
CAE and histopathology using the paired Student’s t-test. In 
addition, the agreement between the measurements by the 
radiologists or the CAE and the histopathological size in the 
assessment of residual tumor extent after the completion 
of chemotherapy was assesses by the Bland-Altman 
plotting method (28). The mean difference between the 
two measurements and the 95% limits of agreement were 
calculated. The difference between the two measurements 
was plotted against the mean of the two measurements. 
One of the two radiologists reviewed the standardized 
histopathology report and analyzed the agreement between 
the measurements. 
For the assessment of tumor response, RECIST between 
1D measurements performed by radiologists and 1D 
measurement or 3D volumetric measurements determined by 
the CAE were compared using weighted kappa (k) statistics 
between two groups (responders and nonresponders). The 
rates of concordance and discordance for the assessment 
were analyzed. Statistical analyses were carried out using 
SPSS for Windows 12.0 (SPSS, Chicago, IL) and MedCalc 
for Windows, version 9.3.1 (MedCalc Software, Mariakerke, 
Belgium).
RESULTS
Assessment of Residual Tumor Extent
The mean number of measured lesions per breast was 1.9 
± 1.3 (standard deviation) (range, 1-5). After chemotherapy, 
the mean tumor diameter measured by radiologists and CAE 
was 2.0 ± 1.7 cm (mean ± standard deviation) (range, 0-9.0 
cm) and 2.2 ± 2.0 cm (range, 0-9.6 cm) respectively, and 2.6 
± 2.3 cm (range, 0-9.2 cm) based on the histopathological 
assessment. A statistically signifi  cant difference was found 
between radiologists’ measurements and histological 
diameters (p = 0.01), however, no signifi  cant difference 
was found between the CAE measurements and histological 
diameters (p = 0.19). Korean J Radiol 12(1), Jan/Feb 2011 www.kjronline.org 38
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Figure 1 shows the plots that propose the differences 
between measurements by the radiologists or CAE 
and histopathology, relative to the mean of the two 
measurements. The mean difference between the 
histopathological and radiologists’ measured diameters 
was 0.6 cm with 95% limits of agreement from -3.0 to 
4.3. The mean difference between histopathological and 
CAE assessed diameters was 0.4 cm with 95% limits of 
agreement from -3.9 to 4.7. All of the two plots showed 
good agreement between each method.
Assessment of Response to Chemotherapy
The mean tumor diameter reduction was 40 ± 29.2% 
as determined by the radiologists (5.3 ± 2.7 cm before 
chemotherapy and 2.0 ± 1.7 cm after chemotherapy) and 
43 ± 34.0% by CAE (5.6 ± 3.6 cm before chemotherapy 
and 2.2 ± 2.0 cm after chemotherapy). The mean tumor 
volume reduction was 85 ± 23.4% as determined by the CAE 
(17.0 ± 21.2 cc before chemotherapy and 1.5 ± 2.5 cc after 
chemotherapy).
According to the 1D measurement by the radiologists, 
47 patients (83%) were responders (10 patients with CR 
and 37 patients with PR) and 10 patients (18%) were non-
AB
Fig. 1. Bland-Altman plots of manual measurements by radiologists (RAD), computer-assisted evaluation program (CAE), and 
histopathologic unidimensional measurements of residual tumor extent after neoadjuvant chemotherapy. 
Solid line (center) represents mean of differences. Top dashed line represents upper limit of agreement (mean difference plus two times 
standard deviation); bottom line represents lower limit of agreement (mean difference minus two times standard deviation).
A is for agreement between RAD and histopathology (mean difference = 0.6 cm, 95% limits of agreement: -3.0 to 4.3 cm) and B is for 
agreement between CAE and histopathology (mean difference = 0.4 cm, 95% limits of agreement: -3.9 to 4.7 cm).
Table 2. Comparison of Responsiveness between 1D Measurements by Radiologist and CAE
Radiologist (1D)
Total
CR PR SD PD
CAE (1D) CR 8300 1 1   (19%)
PR 2 28 5 0 35 (61%)
S D 0650 1 1   (19%)
P D 0000   0  (0%)
Total 10 (18%) 37 (65%) 10 (18%) 0 (0%) 57 (100%)
Note.— Patients were divided into two groups as responders and non-responders. Complete response (CR) and partial response (PR) 
were defi  ned as responder group, whereas stable disease (SD) and progressive disease (PD) were defi  ned as non-responder group. 
Weighted kappa value (k) between radiologist and computer-aided evaluation program for two groups of responsiveness was 0.358. 
1D = unidimensional, CAE = computer-aided evaluation programKorean J Radiol 12(1), Jan/Feb 2011 www.kjronline.org 39
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responders (10 patients with SD and no patients with PD) 
(Tables 2, 3). According to the 1D measurement by CAE, 
46 patients (81%) were responders (11 patients with CR 
and 35 patients with PR) and 11 patients (19%) were non-
responders (11 patients with SD and no patients with PD) 
(Table 2). According to the 3D volumetry, 50 patients (88%) 
Table 3. Comparison of Responsiveness between Unidimensional (1D) Measurements by Radiologist and Volumetric 
(3D) Measurements by CAE 
Radiologist (1D)
Total
CR PR SD PD
CAE (3D) CR 9 3 0 0 12 (21%)
PR 1 29 8 0 38 (67%)
SD 0 5 2 0   7 (12%)
PD 0 0 0 0   0 (0%)
Total 10 (18%) 37 (65%) 10 (18%) 0 (0%) 57 (100%)
Note.— Patients were divided into two groups as responders and non-responders (similar to Table 3). Weighted kappa value (k) 
between 1D measurement by radiologist and 3D measurement by CAE for two groups of responsiveness was 0.106.
1D = unidimensional, 3D = three dimensional, CAE = computer-aided evaluation program, CR = complete response, PD = 
progressive disease, PR = partial response, SD = stable disease
A B 
Fig. 2. Concordant case between 
unidimensional and three dimensional 
measurements is presented. 
Imaging measurements are presented 
for 52-year-old woman diagnosed with 
infi  ltrating duct carcinoma upon initial 
examination (indicator in A) and follow-
up examination (indicators in B). After 
chemotherapy, 1D measurement shows 
57% diameter reduction from 6.7 cm 
(A) to 2.9 cm (B). According to RECIST, 
this tumor is categorized as responder. 
Computer-aided volumetry shows 94% 
volume reduction from 61.8 cc (C) to 
3.5 cc (D). According to volumetric 
criteria; this tumor is also categorized as 
responder.
C DKorean J Radiol 12(1), Jan/Feb 2011 www.kjronline.org 40
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were responders (12 patients with CR and 38 patients 
with PR) and seven patients (12%) were non-responders 
(seven patients with SD and no patients with PD) (Table 
3). The 1D measurements by the radiologists and by CAE 
were concordant in 46 (81%) and discordant in 11 (19%) 
of the 57 patients, resulting in a weighted kappa value of 
0.358, which indicated a fair agreement between the two 
methods. The 1D measurement by the radiologists and 3D 
measurements by CAE were concordant (Fig. 2) in 44 (77%) 
and discordant (Fig. 3) in 13 (23%) of the 57 patients, 
resulting in a weighted kappa value of 0.106, which 
indicated a poor agreement between the two methods. 
Eight patients were non-responders according to the 1D 
measurements, but were responders by 3D volumetry. Five 
patients were non-responders by 3D volumetry, but were 
responders by 1D measurement by radiologist (Table 3).
DISCUSSION
This study evaluated the accuracy of CAE in breast MRI for 
the assessment of residual tumor extent and the monitoring 
of response after neoadjuvant chemotherapy. According to 
our results for the assessment of residual tumor extent in 
breast cancer patients receiving neoadjuvant chemotherapy, 
the mean difference between 1D measurement by the 
radiologists and the histopathological assessment was 0.6 
cm, whereas the difference between the CAE measurements 
and the histopathological assessment was 0.4 cm. The 95% 
confi  dence interval for the measured difference between 
the radiologists and histopathological assessment was in 
the range from -3.0 to 4.3 cm (93%, 53 of 57), whereas 
the difference between the measurement by CAE and the 
histopathological assessment was in the range of -3.9 to 
4.7 cm (91%, 52 of 57). The measurement by radiologists 
A B 
Fig. 3. Discordant case between 
unidimensional and three dimensional 
measurements is presented. 
Imaging measurements are presented 
for 36-year-old woman diagnosed with 
infi  ltrating duct carcinoma upon initial 
examination (indicator in A) and follow-
up examination (indicator in B). After 
chemotherapy, 1D measurement shows 
21% diameter reduction from 5.3 cm (A) 
to 4.2 cm (B). According to RECIST, this 
tumor is categorized as non-responder. 
Computer-aided volumetry shows 90% 
volume reduction from 6.4 cc (C) to 0.64 
cc (D). According to volumetric criteria, 
this tumor is categorized as responder.
C DKorean J Radiol 12(1), Jan/Feb 2011 www.kjronline.org 41
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underestimated the 1D measurement compared to the 
histological tumor diameter (p = 0.01); however, no 
difference was found between the CAE measurements and 
the histological diameter (p = 0.19). These results indicate 
that the measurement of CAE is more accurate than the 
measurement by radiologists and can be used in place of 
direct measurement by a radiologist. 
As the underestimation of residual tumor extent after 
neoadjuvant chemotherapy can lead to early local relapse 
or a repeated excision that hampers conservation surgery 
and overestimation of residual tumor extent can lead to 
overtreatment in breast cancer patients, the accurate 
assessment of lesion extent is crucial. A previous study 
evaluating the use of breast MRI in patients with breast 
cancer following chemotherapy reported a false negative 
rate of 31% (4 of 13) and underestimated cases (15%, 2 of 
13) (21), which was consistent with the results of our study 
where the measurement by radiologists underestimated 
the 1D measurement compared with the histological tumor 
diameter (p = 0.01). Such underestimation on MRI might be 
explained by reduced contrast enhancement and fl  attening 
of the washout time-signal intensity curve due to an 
antiangiogenic effect of cytotoxic chemotherapy (21, 29). 
Therefore, lesion size measurement on delayed phase images 
of dynamic contrast enhanced MRI would be more accurate 
than those on early phase images used in our study. 
The use of RECIST, which measures the longest diameter 
of a tumor, has been accepted to be as accurate as 
bidimensional measurements according to the WHO 
criteria. However, many limitations have been reported 
for the use of RECIST and the necessity of modifi  cation for 
volumetric or functional assessment has been raised (12, 
13). Volumetric measurements were expected to provide a 
more precise quantifi  cation of tumor burden and to be less 
affected by inter-observer variability, especially for multiple, 
irregular, scattered or confl  uent lesions after chemotherapy. 
Moreover, several investigators have found that 3D 
volumetry correlated with prognosis (30, 31). In one study, 
Partridge et al. (30) found that the initial tumor volume 
and fi  nal change in MRI volume in breast cancer patients 
undergoing neoadjuvant chemotherapy were signifi  cant 
independent predictors of recurrence free survival based on 
the use of multivariate analysis. In another study, Hylton et 
al. (31) reported that MRI volume change after one cycle 
of chemotherapy showed the strongest correlation for the 
prediction of end-of-treatment response.
Even with these promising results, 3D volumetry has 
been considered laborious in clinical practice and has 
been under-established to determine treatment response 
(13). In our study, a commercially available CAE provided 
simple measurements with automatic segmentation of 
irregular masses that allowed the use of the program to be 
acceptable for a clinical setting. However, in the monitoring 
of response to chemotherapy, the 3D volumetric response 
determination by CAE did not show good agreement with 
the 1D response category (k = 0.106), although the 1D 
measurements by the radiologists and by CAE showed a fair 
agreement (k = 0.358). This might be due to the use of a 
65% volume reduction criterion. Of the lesions assessed, 
23% (13 of 57) were discordant and a larger reduction in 
tumor size was required for the categorization of responders 
on 1D measurement. This condition may have resulted due 
to the fact that the present criteria were based on the 
assumption that tumors were spherical and that responding 
patients have equivalent percentage reductions in the 
measurements of length, width, and depth of tumors. 
Therefore, when a tumor had an irregular shape or was 
diffusely scattered for distribution, discrepancy of the 
assumption of spherical tumor and measured tumor tended 
to increase and 1D measurement of residual tumors tended 
to be overestimated than real tumor volume because the 
1D measurement was determined by the maximum diameter. 
Similarly, in a previous study involving the comparison 
of 1D and 2D measurements, simulation models with 
increasing irregularities increased the discordance rates 
of PR and SD categories between the two methods (13). 
If the comparison would have been between 1D and 3D 
measurements in the simulation model, it could be expected 
that even a small difference may have lead to a larger 
difference in triplicated calculations, hence leading to a 
different treatment decision.
This study had some limitations; this was a retrospective 
study with a small sample size and was conducted at a 
single institute. In addition, it was not possible to correlate 
computer-aided volumetric results with tumor volumes 
determined by histopathology, as the 3D volumetric results 
were not available in the clinical situation. Third, there 
were 19 cases (25%, 19 of 76) of data loading errors in the 
application of the CAE program. Thus, we cannot generalize 
our results for the evaluation of all ranges of breast MRI 
in the neoadjuvant chemotherapy setting. Sagittal breast 
MRI scanning at a right angle might be considered for the 
possible solution. Fourth, the time interval between the 
completion of chemotherapy and 2nd (preoperative) MRI Korean J Radiol 12(1), Jan/Feb 2011 www.kjronline.org 42
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was variable (21.1 days: range, 8-51 days), which could 
have affected results. However, there is no established 
recommendation for the adequate timing of preoperative 
MRI after neoadjuvant chemotherapy. This question is 
beyond scope of this study. 
In conclusion, CAE for breast MRI is suffi  ciently accurate 
for the assessment of residual tumor extent in breast cancer 
patients receiving neoadjuvant chemotherapy. However, 
for the assessment of response to chemotherapy, the 
radiologists’ assessment and CAE assessment showed fair to 
poor agreements.
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